Study of ZG006 in Participants With Small Cell Lung Cancer or

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03651219` - Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT03958045` - Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma	Phase 2
Completed	`NCT04381910` - Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04885998` - AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)	Phase 1
Active, not recruiting	`NCT03703297` - Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Phase 3
Recruiting	`NCT05903092` - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Terminated	`NCT04422210` - A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).	Phase 1
Not yet recruiting	`NCT02875457` - Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin	Phase 3
Recruiting	`NCT02605811` - Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer	Phase 2
Recruiting	`NCT02577627` - Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC	N/A
Completed	`NCT02551432` - Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer	Phase 2
Withdrawn	`NCT02542137` - Abscopal Effect for Metastatic Small Cell Lung Cancer	Phase 2
Recruiting	`NCT02262897` - The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer	Phase 2
Terminated	`NCT00969306` - Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients	Phase 1
Completed	`NCT01943578` - Value of Physical Capacity Tests in Lung Cancer	N/A
Completed	`NCT01831089` - Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors	Phase 1
Completed	`NCT01497873` - A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer	Phase 2
Terminated	`NCT00958022` - Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer	Phase 1
Completed	`NCT00930891` - Bevacizumab in Extensive Small Cell Lung Cancer	Phase 2/Phase 3

NCT number	NCT05978284
Study type	Interventional
Source	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Contact	Hewen Yin
Phone	+86-02158942758
Email	yinhw@zelgen.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	October 27, 2023
Completion date	October 2025

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms